| Literature DB >> 25859175 |
Barbara Bednarczyk-Cwynar1, Lucjusz Zaprutko1.
Abstract
During the last few decades more and more attention has been paid to triterpenes-a group of compounds with five- or four-ring skeleton and carboxyl, hydroxyl or oxo groups. Triterpenes with unsubstituted C-3 hydroxyl group can be easily transformed into appropriate ketones and then into oximes. The carbonyl group can be created not only from the hydroxyl group at C-3 position, but also at C-2, C-12 or C-28 positions. Several methods of creation of two = NOH groups within one molecule of triterpene are known. There are also known triterpenes with two carbonyl groups, e.g. at C-3 and C-11 positions, which differ in reactivity: among them only C-3 group can be transformed into oxime. A reactive hydroxyimine group can undergo the action of acylating agents, such as carboxylic acids or their derivatives, also the ones with significant pharmacological activity. Acyl derivatives of triterpenic oximes exhibit important pharmacological activity. The biological tests performed with the use of cell cultures inoculated with viruses showed inhibitory activity of some triterpenic acyloximes against type 1 HSV (H7N1), ECHO-6 and HIV-1 viruses. Another acylated oximes derived from triterpenes shown cytotoxic or antiproliferative activity against many lines of cancer cells. In many cases the pharmacological effects of the tested acyloxyiminotriterpenes were comparable to those of appropriate standard drugs. One of the newest application of acyl derivatives of triterpenic oximes is their ability to form organogels.Entities:
Keywords: Acyl derivatives of triterpenic oximes; Derivatives of triterpenes; Triterpenes; Triterpenic oximes
Year: 2014 PMID: 25859175 PMCID: PMC4379416 DOI: 10.1007/s11101-014-9353-5
Source DB: PubMed Journal: Phytochem Rev ISSN: 1568-7767 Impact factor: 5.374
Scheme 1Some important chemical transformations of oleanonic acid (3) or its methyl ester (4) within A-ring
Scheme 2The synthesis of acylated oximes 16a, 16b derived from betulin (13)
Reagents, their molar ratio, reaction conditions, specialized methods of purification and yields of O-acylderivatives of triterpenic oximes
| Route no. | Reagents and their molar ratio | Reaction conditions | Specialized purification; yield | Ref. |
|---|---|---|---|---|
| 1 | Oxime DMAP: 0.5 mmol 3,3-Dimethylglutaryl anhydride: 8–10 mmol | The mixture of reagents in dried pyridine was heated at 95 °C overnight | Column chrom. (silicagel, CHCl3 and acetone = 13:1); Yield of | Sun et al. ( |
| 2 | Oxime Carboxylic acid anhydride: 1.5 mmol Triethylamine: 0.4 ml | The mixture of reagents in dried benzene or diethyl eter was stirred for 4 h at room temp. | Column chrom. (Al2O3, CHCl3 and CH3OH = 10:1); Yields of | Flekhter et al. ( |
| 3 | Oxime Carboxylic acid anhydride: 1.5 mmol DMAP: 0.2 mmol | The mixture of reagents in dried pyridine was refluxed for 12 h | Column chrom. (silicagel, CHCl3 and CH3OH = 99:1 or pure CHCl3); Yields of | Genet et al. ( |
| 4 | Oxime 5-Phenyl-2,3-dihydrofuran-2,3-dione: 1.0 mmol | The mixture of reagents in dried toluene was refluxed for 30 min | No column chrom.; Yield of | Nekrasov and Obukhova ( |
| 5 | Oxime Adipoyl dichloride: 13.75 mmol | The mixture of reagents in dried THF was heated at 60 °C for 30 min | Twice column chrom. (1: RP-18, H2O and CH3OH, 2: silicagel, Yield of | Ma et al. ( |
Oxime Adipic acid: 9.25 mmol DCC: 2.50 mmol | The mixture of reagents in dried THF was stirred at room temp. for 3 h | Twice column chrom. (1: ODS, 2: silicagel, H2O and CH3OH = 1:1–100:0); Yield of | ||
| 6 | Oxime Adipoyl-AZT: 0.07 mmol DMAP: 0.06 mmol DCC: 0.08 mmol | The mixture of reagents in dried THF was stirred at room temp. overnight | Column chrom. (ODS), next: HPLC (H2O and CH3OH = 20:80–0:100; Yields: | Ma et al. ( |
FK 3000: 0.02–0.05 mmol DCC:0.02–0.05 mmol | The mixture of reagents in dried methylene chloride was stirred at room temp. for 10 h | Twice column chrom. (1: RP-18, H2O and methanol = 3:7–0:1), 2: silicagel, Yield of | ||
| 7 |
Oxime Sodium acetate: 1.12 mmol Na2PdCl2: 1.11 mmol
Crude product of first step: 1.00 mmol DMAP: 0.05 mmol Trietylamine: 0.64 mmol
Compound Pb(CH3COO)4: 4.59 mmol NaBH4: 180 mg 1 N NaOH |
|
Yields of
Yield of | Honda et al. ( |
| 8 | Dioxime DMAP: 0.2 mmol Acetic anhydride: 20 mmol | The mixture of reagents in pyridine was stirred at room temp. for 24 h | Column chrom. (silicagel, CH2Cl2 and CH3OH = 70:1); Yield of | Hu et al. ( |
| 9 | Oxime Carboxylic acid: 1.2 mmol DCC: 1.5 mmol | The mixture of reagents in dried dioxane or THF was stirred at room temp. for 30–90 min | No column chrom.; Yields of acylated oximes | Bednarczyk-Cwynar et al. ( |
| 10 | Oxime Octanoic acid: 3.0 mmol DCC: 5.0 mmol | The mixture of reagents in dried THF was stirred at room temp. for 30 min | No column chrom.; Yield of | Bednarczyk-Cwynar et al. ( |
| 11 | Oxime Carboxylic acid: 1.2 mmol DCC: 1.4 mmol | The mixture of reagents in dried CH2Cl2 was refluxed for 8–14 h | Column chrom. (silicagel, petroleum ether with EtOAc); Yields of | Zhao et al. ( |
| 12 | Oxime Carboxylic acid: 1.2 mmol DCC: 1.5 mmol | The mixture of reagents in dried dioxane was stirred at room temp. for 30 min | No column chrom.; Yield of | Bednarczyk-Cwynar et al. ( |
| 13 | Oxime Acetic or propionic anhydride: 1.5 mmol DMAP: catalytic | The mixture of reagents in pyridine was refluxed for 4–6 h | Column chrom. silicagel (chloroform with methanol = 200:1); Yields of | Liu et al. ( |
DMAP 4-(N,N-dimethyl)aminopyridine, DCC dicyclohexylcarbodiimide, RP-18 reversed-phase with octadecyl carbon chain (C18)-bonded silica chromatography, ODS octadecylsilanyl chromatography, AZT azidothymidine, HPLC high-performance liquid chromatography
Pharmacological activity of acylated oximes of triterpenes and their mother compounds
| Compound | Results | Activity | Literature |
|---|---|---|---|
|
| IC50 = 43.7 μM | Antiviral (HIV acutely infected H9 lymphocytes) | Sun et al. ( |
|
| IC50 = 5.47 μM | ||
|
| IC50 = 15.4 μM | ||
|
| EC50 = 23.0 μM | Antiviral (HIV acutely infected H9 lymphocytes) | |
|
| EC50 = 1.07 μM | ||
|
| EC50 = 4.57 μM | ||
|
| VR = 7 % | Antiviral (SFV) | Pohjala et al. ( |
|
| VR = 121 % | ||
|
| VR = 73 % | ||
|
| CV = 83 % | ||
|
| CV = 80 % | ||
|
| CV = 85 % | ||
|
| EC50 = 2.17 μM | Antiviral (influenza A) | Flekhter et al. ( |
|
| EC50 > 25.84 μM | ||
|
| EC50 = 150.54 μM | ||
|
| MTC/EC50 = 392.16 | ||
|
| MTC/EC50 < 1 | ||
|
| MTC/EC50 = 2.83 | ||
|
| EC50 = 81.56 μM | Antiviral (HSV 1) | |
|
| EC50 = 31.32 μM | ||
|
| EC50 = 160.07 μM | ||
|
| MTC/EC50 = 1.30 | ||
|
| MTC/EC50 = 6.60 | ||
|
| MTC/EC50 = 2.66 | ||
|
| EC50 = 4.19 μM | Antiviral (ECHO 6) | |
|
| EC50 = 36.84 μM | ||
|
| EC50 = 133.10 μM | ||
|
| MTC/EC50 = 6.09 | ||
|
| MTC/EC50 = 11.22 | ||
|
| MTC/EC50 = 1.60 | ||
| BA | ED50 = 1.23 μg/ml | Cytotoxic (MOLT-4) | Mukherjee et al. ( |
|
| ED50 = 2.1 μg/ml | ||
|
| ED50 = 2.2 μg/ml | ||
|
| ED50 = 2.7 μg/ml | ||
| BA | ED50 = 0.65 μg/ml | Cytotoxic (JurkatE6.1) | |
|
| ED50 = 1.8 μg/ml | ||
|
| ED50 = 2.9 μg/ml | ||
|
| ED50 = 4.9 μg/ml | ||
| BA | ED50 = 0.98 μg/ml | Cytotoxic (CEM.CM3) | |
|
| ED50 = 2.6 μg/ml | ||
|
| ED50 = 4.2 μg/ml | ||
|
| ED50 = 1.5 μg/ml | ||
| BA | ED50 = 0.84 μg/ml | Cytotoxic (BRISTOL8) | |
|
| ED50 = 1.6 μg/ml | ||
|
| ED50 = 3.4 μg/ml | ||
|
| ED50 = 3.3 μg/ml | ||
| BA | ED50 = 0.69 μg/ml | Cytotoxic (U937) | |
|
| ED50 = 2.4 μg/ml | ||
|
| ED50 = 5.5 μg/ml | ||
|
| ED50 = 4.8 μg/ml | ||
| BA | ED50 = 1.13 μg/ml | Cytotoxic (DU145) | |
|
| ED50 = 1.1 μg/ml | ||
|
| ED50 = 2.9 μg/ml | ||
|
| ED50 = 2.8 μg/ml | ||
| BA | ED50 > 10 μg/ml | Cytotoxic (PA-1) | |
|
| ED50 = 0.7 μg/ml | ||
|
| ED50 = 3.7 μg/ml | ||
|
| ED50 = 1.8 μg/ml | ||
| BA | ED50 > 10 μg/ml | Cytotoxic (A549) | |
|
| ED50 = 1.8 μg/ml | ||
|
| ED50 > 10 μg/ml | ||
|
| ED50 > 10 μg/ml | ||
| BA | ED50 = 1.3 μg/ml | Cytotoxic (L132) | |
|
| ED50 = 1.5 μg/ml | ||
|
| ED50 = 5.3 μg/ml | ||
|
| ED50 > 10 μg/ml | ||
|
| EC50 = 1.75 μM | Antidiabetic (TGR 5) | Genet et al. ( |
|
| EC50 = 5.00 μM | ||
|
| EC50 = 3.17 μM | ||
|
| EC50 = 7.88 μM | ||
|
| EC50 = 7.73 μM | ||
|
| EC50 = 3.65 μM | ||
|
| efficacy = 132 | ||
|
| efficacy = 159 | ||
|
| efficacy = 20 | ||
|
| efficacy = 139 | ||
|
| efficacy = 126 | ||
|
| efficacy = 13 | ||
|
| IC50 = 8.0 μM | Antiviral (HIV-1) | Ma et al. ( |
|
| IC50 = 5.5 μM | ||
|
| IC50 = 9.5. μM | ||
|
| IC50 = 5.5. μM | ||
|
| IC50 = 4.0 μM | ||
|
| IC50 = 8.0 μM | Antiviral (HIV-1 PR) | Ma et al. ( |
|
| IC50 = 5.5 μM | ||
|
| IC50 = 9.5 μM | ||
|
| IC50 = 5.5 μM | ||
|
| IC50 = 1.9 μM | ||
|
| IC50 = 4.0 μM | ||
|
| IC50 = 16 μM | ||
|
| IC50 > 100 μM | ||
|
| IC100 not effective | Antiviral (HIV-1 RT) | |
|
| IC100 not effective | ||
|
| IC100 not effective | ||
|
| IC100 not effective | ||
|
| IC100 = 1.84 μM | ||
|
| IC100 not effective | ||
|
| IC100 = 4.53 μM | ||
|
| IC100 not effective | ||
|
| CC0 ≥ 110 μM | Antiviral (HIV-1 RT) | |
|
| CC0 = 266 μM | ||
|
| CC0 = 51.8 μM | ||
|
| CC0 = 209 μM | ||
|
| CC0 = 29.6 μM | ||
|
| CC0 = 40.9 μM | ||
|
| CC0 = 145 μM | ||
|
| CC0 = 31.0 μM | ||
|
| MGC = 1.20 g/100 cm3 (methylene chloride) | Gelation | Hu et al. ( |
| MGC = 0.37 g/100 cm3 (chloroform) | |||
| MGC = 2.08 g/100 cm3 (carbon tetrachloride) | |||
| MGC = 0.10 g/100 cm3 (benzene) | |||
| MGC = 0.20 g/100 cm3 (toluene) | |||
|
| GI50 = (1.55–12.80) × 10−6 the most sensitive cell line: HOP-92) | Anticancer (lung cancers) | Bednarczyk-Cwynar et al. ( |
| GI50 = (1.66–34.80) × 10−6 (the most sensitive cell line: HCT-116) | Anticancer (colon cancers) | ||
| GI50 = (1.56–2.67) × 10−6 (the most sensitive cell line: HS-578T2) | Anticancer (brest cancers) | ||
| GI50 = (1.67–16.50) × 10−6 (the most sensitive cell line: OVCAR-3) | Anticancer (ovary cancers) | ||
| GI50 = (2.02–2.78) × 10−6 (the most sensitive cell line: HL-60 TB) | Anticancer (leukemias) | ||
| GI50 = (1.49–2.60) × 10−6 (the most sensitive cell line: UO-31) | Anticancer (kidney cancers) | ||
| GI50 = (1.47–11.50) × 10−6 (the most sensitive cell line: LOX IMVI) | Anticancer (melanomas) | ||
| GI50 = (1.76–10.40) × 10−6 (the most sensitive cell line: SF-539) | Anticancer (CNS cancers) | ||
| TGI = (4.04–22.90) × 10−6 (the most sensitive cell line: HOP-92) | Anticancer (lung cancers) | ||
| TGI = (3.02–12.60) × 10−6 (the most sensitive cell line: HCC-2998) | Anticancer (colon cancers) | ||
| TGI = (4.29–14.20) × 10−6 (the most sensitive cell line: MCF-7) | Anticancer (brest cancers) | ||
| TGI = (3.08–30.40) × 10−6 (the most sensitive cell line: OVCAR-3) | Anticancer (ovary cancers) | ||
| TGI = (5.36–8.16) × 10−6 (the most sensitive cell line: HL-60 TB) | Anticancer (leukemias) | ||
| TGI = (2.93–16.30) × 10−6 (the most sensitive cell line: UO-31) | Anticancer (kidney cancers) | ||
| TGI = (2.94–24.40) × 10−6 (the most sensitive cell line: LOX IMVI) | Anticancer (melanomas) | ||
| TGI = (3.37–22.10) × 10−6 (the most sensitive cell line: U251) | Anticancer (CNS cancers) | ||
| LC50 = (11.50–100.00) × 10−6 (the most sensitive cell line: HOP-92) | Anticancer (lung cancers) | ||
| LC50 = (6.14–38.80) × 10−6 (the most sensitive cell line: HCT-116) | Anticancer (colon cancers) | ||
| LC50 = (11.10–46.80) × 10−6 (the most sensitive cell line: MCF-7) | Anticancer (brest cancers) | ||
| LC50 = (5.70–60.20) × 10−6 (the most sensitive cell line: OVCAR-3.) | Anticancer (ovary cancers) | ||
| LC50 = (2.62–100.00) × 10−6 (the most sensitive cell line: HL-60 TB) | Anticancer (leukemias) | ||
| LC50 = (5.79–57.20) × 10−6 (the most sensitive cell line: UO-31) | Anticancer (kidney cancers) | ||
| LC50 = (5.89–51.50) × 10−6 (the most sensitive cell line: LOX IMVI) | Anticancer (melanomas) | ||
| LC50 = (6.39–54.90) × 10−6 (the most sensitive cell line: U251) | Anticancer (CNS cancers) | ||
|
| MGIR = 22.4 % | Fungicidal ( | Zhao et al. ( |
|
| MGIR = 29.4 % | ||
|
| MGIR = 37.2 % | ||
|
| MGIR = 40.8 % | ||
|
| MGIR = 19.2 % | ||
|
| MGIR = 30.8 % | ||
|
| MGIR = 29.1 % | ||
|
| MGIR = 22.9 % | ||
|
| MGIR = 24.8 % | ||
|
| MGIR = 21.0 % | ||
|
| MGIR = 20.5 % | ||
|
| MGIR = 8.7 % | ||
|
| MGIR = 12.2 % | ||
|
| MGIR = 19.8 % | ||
|
| MGIR = 16.2 % | ||
|
| MGIR = 20.2 % | ||
|
| MGIR = 34.2 % | ||
|
| MGIR = 28.2 % | ||
|
| MGIR = 12.7 % | ||
|
| MGIR = 19.3 % | ||
|
| MGIR = 13.2 % | ||
|
| MGIR = 16.4 % | ||
|
| MGIR = 33.0 % | ||
|
| MGIR = 33.1 % | ||
|
| MGIR = 12.5 % | ||
|
| MGIR = 13.8 % | ||
|
| MGIR = 1.0–25.3 % (the most sensitive cell line: | Fungicidal; conc. = 50 μg/ml | |
|
| MGIR = 1.8–61.2 % (the most sensitive cell line: | ||
|
| MGIR = 8.4–61.2 % (the most sensitive cell line: | ||
|
| MGIR = 3.1–42.7 % (the most sensitive cell line: | ||
|
| MGIR = 15.8–53.5 % (the most sensitive cell line: | ||
|
| MGIR = 6.5–73.0 % (the most sensitive cell line: | ||
|
| MGIR = 4.0–33.5 % (the most sensitive cell line: | ||
|
| MGIR = 6.1–67.6 % (the most sensitive cell line: | ||
|
| MGIR = 2.0–27.8 % (the most sensitive cell line: | ||
|
| MGIR = 1.4–25.1 % (the most sensitive cell line: | ||
|
| MGIR = 2.3–30.3 % (the most sensitive cell line: | ||
|
| MGIR = 9.4–79.2 % (the most sensitive cell line: | ||
|
| MGIR = 12.0–71.1 % (the most sensitive cell line: | ||
|
| MGIR = 23.5–93.6 % (the most sensitive cell line: | ||
|
| MGIR = 25.9–74.3 % (the most sensitive cell line: | ||
|
| MGIR = 17.4–84.1 % (the most sensitive cell line: | ||
|
| MGIR = 18.1–73.1 % (the most sensitive cell line: | ||
|
| MGIR = 17.7–86.1 % (the most sensitive cell line: | ||
|
| MGIR = 21.7–67.8 % (the most sensitive cell line: | ||
|
| MGIR = 25.3–74.4 % (the most sensitive cell line: | ||
|
| MGIR = 23.5–68.2 % (the most sensitive cell line: | ||
|
| MGIR = 21.4–64.5 % (the most sensitive cell line: | ||
|
| MGIR = 28.2–69.5 % (the most sensitive cell line: | ||
|
| MGIR = 24.6–66.7 % (the most sensitive cell line: | ||
|
| MGIR = 30.8–77.6 % (the most sensitive cell line: | ||
|
| MGIR = 28.7–85.5 % (the most sensitive cell line: | ||
|
| IC50 = 14.93 μM | Anticancer (KB) | |
|
| IC50 = 2.06 μM | Bednarczyk-Cwynar et al. ( | |
|
| IC50 > 15.00 μM | ||
|
| IC50 = 9.42 μM | ||
|
| IC50 = 4.90 μM | ||
|
| IC50 = 0.72 μM | ||
|
| IC50 = 10.10 μM | ||
|
| IC50 = 13.95 μM | Anticancer (MCF-7) | |
|
| IC50 = 11.27 μM | ||
|
| IC50 > 15.00 μM | ||
|
| IC50 = 7.26 μM | ||
|
| IC50 = 3.76 μM | ||
|
| IC50 = 2.13 μM | ||
|
| IC50 = 9.28 μM | ||
|
| IC50 = 11.82 μM | Anticancer (MCF-7) | |
|
| IC50 = 1.34 μM | ||
|
| IC50 > 15.00 μM | ||
|
| IC50 = 9.19 μM | ||
|
| IC50 = 4.41 μM | ||
|
| IC50 = 1.87 μM | ||
|
| IC50 = 9.84 μM | ||
|
| GI50 = 63.2 μM | Anticancer (HL-60) | Liu et al. ( |
|
| GI50 = 63.9 μM | ||
|
| GI50 = 58.8 μM | ||
|
| GI50 = 57.7 μM | ||
|
| AC = 24.9 % | ||
|
| AC = 24.5 % | ||
|
| AC = 19.1 % | ||
|
| AC = 27.7 % |
BA betulinic acid, MB methyl betulinate, 20-OAB 20-oxoallobetulin, OA oleanolic acid, MO methyl oleanolate, GA glycyrrhetinic acid, IC 50 % inhibitory concentration, EC 50 % effective concentration, VR virus replication, CV cell viability, MTC maximum tolerable concentration, ED 50 % effective dose, IC 100 % inhibition concentration, CC minimum cytotoxic concentration, MGC minimum gelator concentration, GI 50 % growth inhibition, TGI total growth inhibitor, LC 50 % lethal concentration, MGIR mycelium growth inhibition rate, AC amount of apoptotic cells
Scheme 3The synthesis of acylated oximes 23a–23c, 24a–24c, 25a–25c derived from betulin (13)
Scheme 4The synthesis of acylated oximes 23a and 23d–23 h derived from betulonic acid (17)
Scheme 5The synthesis of acylated oxime 26 derived from betulin (13)
Scheme 6The synthesis of acylated oximes 27a,b and 28a–28c derived from oleanolic acid (1)
Scheme 7The synthesis of acylated oximes 31 and 32 derived from oleanolic acid (1)
Scheme 8The synthesis of acylated oximes 35a,b and 36a,b derived from methyl maslinate (33)
Scheme 9The synthesis of acylated oxime 41 derived from oleanolic acid (1)
Scheme 10a The synthesis of oximes 11, 12, 42 and 43 derived from oleanolic acid (1). b The synthesis of acylated oximes 44a–44h, 45a–45h, 46a–46h and 47a–47h derived from oleanolic acid (1)
Scheme 11The synthesis of acylated oxime 48 derived from oleanolic acid (1)
Scheme 12The synthesis of acylated oximes 50a–50j and 51a–51o derived from oleanolic acid (1)
Scheme 13The synthesis of acylated oximes 54a–54e derived from methyl oleanolate (2)
Scheme 14The synthesis of acylated oximes 57a, 57b derived from glycyrrhetinic acid (55)